Elsevier

The Lancet

Volume 359, Issue 9320, 25 May 2002, Pages 1829-1830
The Lancet

Research Letters
Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination

https://doi.org/10.1016/S0140-6736(02)08679-8Get rights and content

Summary

The UK was the first place to Introduce meningococcal serogroup C conjugate (MCC) vaccines. From November, 1999, all people younger than 18 years, about 14 million individuals, were offered MCC immunisation. The uptake rate was more than 70% by November, 2000. We compared the carriage of meningococci in isolates we obtained from 14 064 students aged 15–17 years during vaccination in 1999, with those from 16 583 students of the same age surveyed 1 year later. Carriage of serogroup C meningococci was reduced by 66% (p=0·004). Our results show that MCC vaccines protect against carriage of meningococci that express serogroup C polysaccharide capsules.

Cited by (397)

  • Bacterial Meningitis

    2023, Manson's Tropical Diseases, Fourth Edition
  • Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial

    2022, The Lancet Microbe
    Citation Excerpt :

    Pharyngeal colonisation with the pathogen Neisseria meningitidis occurs in approximately 10% of the population and is a prerequisite for invasive meningococcal disease.1 Although glycoconjugate meningococcal vaccines have markedly reduced the prevalence of invasive meningococcal disease, largely owing to the induction of herd protection through population-level reduction of N meningitidis colonisation,2,3 protein-based serogroup B vaccines (4CMenB and MenB-FHbp) do not reduce colonisation by serogroup B N meningitidis and are therefore unlikely to provide herd protection.4–6 Evidence before this study

  • Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme

    2022, Clinical Microbiology and Infection
    Citation Excerpt :

    An infant-only ‘2 + 1’ schedule of 4CMenB (Bexsero, GSK) commenced in September 2015 [13], which was not anticipated to impact on meningococcal carriage [14]. The UK Meningococcal Carriage (UKMenCar1-4) surveys demonstrated the impact of herd protection from the MCC vaccine and highlighted behaviours that increase the risk of meningococcal carriage and transmission [4,15,16]. UKMenCar4 was conducted in 2014 and 2015 just prior to the introduction of the MenACWY vaccination programme.

View all citing articles on Scopus

Member listed at end of letter

View full text